SmartPeptide
LongevityLimited human evidence

Epitalon

Tetrapeptide studied primarily in Russian gerontology research for telomerase modulation and pineal function.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Small studies (mostly Russian gerontology programs) suggest effects on telomere biology and circadian/pineal markers in older adults. Some claim mortality benefit over multi-year follow-up.

What's still experimental

Independent replication outside of the original Russian research tradition is sparse. Western RCTs of meaningful size and duration are largely absent.

Anecdotal / community reports

Longevity-focused biohacker reports describe sleep and skin improvements; these are uncontrolled.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Epitalon”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “Epitalon”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Protein targets (UniProt)

  • Telomerase reverse transcriptase
    O14746gene: TERTHomo sapiens· 1132 aaReviewed

    Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-de…

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
132
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
0 total registered

Europe PMC — 94 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
886
all years
Last 5 years
601
recent activity
Open access
809
freely readable
OA share
91%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “epitalon” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
2
all years
Top award sum
$0
aggregate USD
Years covered
2
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
30
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • NRF1 works
  • International Atomic Energy Agency1 works
  • IPEV1 works
  • INTAROS1 works
  • French Polar Institute1 works
  • European Union—Next Generation EU—under the National Recovery and Resilience Plan1 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 1 of 1 preprints indexed by Europe PMC.

Known risks

Most studies are small, single-center, and not independently replicated.

Reported side effects

No established safety profile in larger populations.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “Epitalon”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Not FDA-approved. Long-term safety in larger populations is uncharacterized.

Questions for your clinician

  • What independent replications exist outside the original Russian work?
  • What objective biomarkers (e.g., telomere length, biological-age clocks) would we measure?
  • What's the rationale for cycling vs continuous use?

Editorially curated references

Discussions about Epitalon

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Epitalon discussions Native, moderated, no buying or selling